ArticleDevelopment (Cambridge, England)2026
Regulation of Hippo signaling by Atrophin in the developing Drosophila wing.
Article in Development (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Organ development is directed through integration of signaling networks and their transcriptional programs. Investigation of connections between Hippo signaling and the transcriptional co-repressor Atrophin reveals that Atrophin modulates Hippo signaling outputs in the developing Drosophila wing in distinct ways in different regions. Near the dorsal-ventral boundary, loss of Atrophin leads to upregulation of targets of the Hippo pathway transcription factor Yorkie. This is explained by impairment of Notch signaling and consequent downregulation of Vestigial, which normally competes with Yorkie for binding to Scalloped. In proximal regions of the wing disc, loss of Atrophin leads to downregulation of Yorkie activity. This is explained by downregulation of Dachs, as Dachs inhibits Warts, the central kinase controlling Yorkie activity. Downregulation of Dachs is explained by modulation of its upstream regulators Dachsous and Four-jointed, which is explained in turn by our discovery that Atrophin interacts genetically and physically with Vestigial and competes with Scalloped for Vestigial binding. These studies define new roles for Atrophin and enhance our understanding of the interplay of transcriptional activators and repressors that modulate Hippo signaling to shape wing development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.